Role of Nanocarriers in Management of Non-Hodgkin Lymphoma

Dr. Bhupendra Gopalbhai Prajapati is Professor (Research Cadre) at Parul Institute of Pharmacy, Parul University, Gujarat, India, and serves as Adjunct Professor in the Department of Industrial Pharmacy at Silpakorn University, Thailand. His academic, research, and industry expertise focuses on lipid‑based formulations, nano‑ and microparticulate drug delivery systems, and strategies to enhance drug bioavailability. Dr. Prajapati has received several academic and professional honors recognizing excellence in teaching and research. He has made substantial scholarly contributions through research and review publications, book chapters, and edited volumes in pharmaceutical sciences. Actively engaged in postgraduate and doctoral mentoring, he supports research training in advanced drug delivery and formulation science. Dr. Prajapati also serves in editorial and section‑editor roles for international scientific publications, contributing to the advancement and quality of pharmaceutical research dissemination. Dr. Devesh U. Kapoor is Professor of Pharmaceutics at Dr. Dayaram Patel Pharmacy College, Bardoli, Gujarat, affiliated with Gujarat Technological University. His academic and research expertise centers on pharmaceutics, nanodrug delivery, and modified‑release drug delivery systems. Dr. Kapoor has made extensive scholarly contributions through research and review publications, book chapters, and edited volumes with international publishers. He is actively involved in postgraduate and doctoral research supervision in advanced drug delivery technologies. His editorial experience includes serving in senior editorial roles for international journals across pharmacology, pharmaceutics, and biomedical sciences, along with regular peer‑review activity for a wide range of scientific journals. Dr. Kapoor has also secured competitive research and academic development funding and is a frequent invited speaker at national scientific meetings, workshops, and academic programs.

• 1. Introduction to Non-Hodgkin’s Disease and Conventional Therapies2. Immune Checkpoint Inhibitors in Non-Hodgkin’s Lymphoma Management3. Exploring Polymeric Nanoparticles in Non-Hodgkin’s Lymphoma Management4. Magnetic Nanoparticles in Non-Hodgkin’s Lymphoma Therapy: Advancements and Future Directions5. Leveraging Nanostructured Lipid Carrier (NLCs) in Non-Hodgkin’s Lymphoma Management6. Breakthrough in Antibody-Drug Conjugates for Non-Hodgkin’s Lymphoma Management7. Targeted Non-Hodgkin’s Lymphoma Management with Carbon Nanotubes: Potential and Progress8. Advancement in Non-Hodgkin’s Lymphoma Management Using Exosomes9. Biological and Immunological Aspects of Vaccines for Non-Hodgkin’s Lymphoma Management10. Immunotherapy and Radioimmunotherapy Approaches for Non-Hodgkin’s Lymphoma Management11. Innovative mRNA Approach for Non-Hodgkin’s Lymphoma Management12. Monoclonal Antibody and CAR T-Cell Therapy: A Novel Avenue in Non-Hodgkin’s Lymphoma Management13. Combination of Nanocarrier with Chemotherapy for Non-Hodgkin’s Lymphoma Management14. Patient Care in Non-Hodgkin’s Lymphoma Management15. Regulatory Challenges and Approvals for Nanocarrier-Based Therapies